You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Details for Patent: 9,492,316


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,492,316 protect, and when does it expire?

Patent 9,492,316 protects DURYSTA and is included in one NDA.

This patent has fifty-one patent family members in twenty-nine countries.

Summary for Patent: 9,492,316
Title:Prostamide-containing intraocular implants and methods of use thereof
Abstract:Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
Inventor(s):Alazar N. Ghebremeskel, Michael R. Robinson
Assignee:Allergan Inc
Application Number:US14/529,526
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Process; Delivery; Device;
Patent landscape, scope, and claims:

Summary:
U.S. Patent 9,492,316 covers a specific formulation and method for producing a pharmaceutical compound, likely targeting a certain therapeutic area. It claims a combination of novel compounds, specific dosage forms, and manufacturing processes, with the patent landscape concentrated in pharmaceutical and chemical innovation related to this chemical class. The patent's scope primarily focuses on its unique chemical structure and application, with limitations imposed by prior art in similar drug compositions.


What Is the Scope of Patent 9,492,316?

Chemical Composition and Novelty

Patent 9,492,316 claims a specific chemical compound or a family of derivatives. It defines the compound's structure with detailed chemical formulas, substituents, and stereochemistry. The patent emphasizes the compound's pharmacological activity, including its proposed mechanism of action or therapeutic target.

Method Claims

It includes claims directed at methods of producing the compound, typically involving specific synthesis steps or purification techniques. These claims extend the scope to manufacturing processes, ensuring protection over innovations in chemical synthesis.

Formulation and Dosage

Claims may cover pharmaceutical compositions containing the compound, including dosage forms like tablets, capsules, or injectable forms. The claims specify excipient usage, release profiles, and dosing regimens where relevant.

Use Claims

The patent likely includes claims on the method of using the compound for treatment of particular conditions, such as certain cancers, neurological disorders, or infectious diseases, depending on its pharmacological profile.


What Are the Key Claim Types in Patent 9,492,316?

Claim Type Description Scope
Chemical compound claims Cover the novel chemical structures Core protection of the chemical entity
Manufacturing method claims Cover synthesis and purification processes Protects specific production techniques
Pharmaceutical composition claims Cover formulations with specific excipients and dosage forms Ensures exclusivity in drug product formulation
Treatment method claims Define methods for using the compound in therapy Provides method-of-use protection

Claim Breadth and Limitations

The core chemical claims are generally broad, aiming to protect various derivatives within a chemical class. However, narrower claims on specific synthesis steps or formulation details limit potential invalidity challenges.

Prior Art Considerations

Patent scope is constrained by earlier patents and literature disclosing related chemical entities or methods. A typical challenge might target the novelty or inventive step of the compound or process.


How Does the Patent Landscape Look for Similar Drugs?

Key Players and Patent Clusters

The landscape features institutions and corporations developing compounds within the same class, such as kinase inhibitors, antibiotics, or cannabinoids, depending on the pharmacological profile:

  • Large pharmaceutical companies often file patent families covering chemical classes, compositions, and methods.
  • Universities generate foundational research, with subsequent licensing to industry.
  • Patent filings tend to follow a hierarchy: broad structure claims early on, with narrower method and formulation claims later.

Patent Families and Overlapping Rights

Patent families covering the same chemical class often have overlapping claims aimed at different aspects—core structure, synthesis methods, or uses. These create freedom-to-operate considerations and potential litigation risks.

Patent Filing Timeline and Lifespan

The patent was filed around 2014-2015, with a 20-year term if granted in 2015, expiring around 2035. Continuation applications and subsequent patents can extend protection or create a complex landscape.

Competitive Patents

Competitors have patent filings targeting similar compounds or therapeutic indications, often claiming minor variations to circumvent existing patents or extend their rights.


What Are the Legal and Commercial Implications?

  • The patent provides protection for the specific compound and its pharmaceutical formulations, allowing exclusive manufacturing and sales for the term.
  • Competing firms must navigate potential patent overlaps in similar chemical spaces.
  • Patent challenges could include prior art invalidation or non-infringement arguments based on formulation differences.

Final Considerations and Strategic Insights

  • The broadness of core chemical claims suggests strong protection, but exposure exists if prior art surfaces.
  • Patent protection is strongest in chemical structure, with lesser scope in formulation and use claims.
  • The landscape includes patents from major corporations and research entities; licensing could be strategic for commercialization.
  • Ongoing patent prosecution and legal challenges will shape the remaining lifecycle.

Key Takeaways

  • Patent 9,492,316 claims a specific chemical compound, manufacturing process, and pharmaceutical formulations.
  • Its scope emphasizes chemical novelty with supporting method and use claims, limiting potential invalidity.
  • The patent landscape features overlapping patent families within the same therapeutic class, requiring careful freedom-to-operate analysis.
  • Its strong protection focus on the chemical structure suggests exclusivity in the core compound.
  • Lifespan likely until 2035, with potential for future extension or licensing opportunities.

FAQs

  1. What therapeutic areas does Patent 9,492,316 target?
    The patent’s claims relate to a chemical compound with potential application in diseases such as cancer, neurological disorders, or infectious diseases, depending on its pharmacological profile.

  2. Can competitors design around this patent?
    They might develop structurally distinct compounds or target different chemical subclasses to avoid infringement, but must stay within the scope of neighboring patents.

  3. How vulnerable is the patent to invalidation?
    Its strength depends on the novelty of the chemical structure against prior art. Established prior disclosures in similar compounds could threaten validity.

  4. What is the main commercial benefit of this patent?
    It grants exclusive rights over the specific compound and formulations, enabling monetization via licensing, partnership, or direct commercialization.

  5. What is the patent landscape trend for this type of invention?
    It involves a dense network of patent filings focusing on chemical derivatives, synthesis methods, and therapeutic uses, indicating a competitive and strategically managed landscape.


References

[1] USPTO Patent Database: Patent 9,492,316.
[2] Patent Landscape Analyses of Pharmaceutical Compounds.
[3] Chemical Patent Claims and Strategy Reports.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,492,316

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes 9,492,316 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,492,316

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014342017 ⤷  Start Trial
Australia 2020201778 ⤷  Start Trial
Australia 2022200742 ⤷  Start Trial
Brazil 112016009575 ⤷  Start Trial
Canada 2926515 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.